Analyst Viewpoint
Increase in prevalence and incidence of diabetic disorders and rise in geriatric population are driving the glaucoma therapeutics market size. Serval ophthalmic drugs have pharmacological activities against glaucoma. Some newer class of medications help boost the outflow of aqueous humor and reduce intraocular pressure for the treatment of glaucoma.
Vendors in the global glaucoma therapeutics industry are conducting well-designed and rigorous clinical trials to demonstrate the safety and efficacy of these drugs. They are also launching robust fixed-combination drug therapies to expand their product portfolio. These therapies offer ophthalmologists an attractive option for certain glaucoma patients.
Glaucoma is a disease that damages the optic nerve. Progression of the disease can lead to vision loss and blindness. Topical eye drops that belong to the class of prostaglandins, beta blockers, alpha agonists, combination medication, carbonic anhydrase inhibitors, and cholinergics are recommended for the treatment of glaucoma. These eye drops help reduce the production of fluids inside the eyes, which helps mitigate intraocular pressure.
Prostaglandins analogs are the molecules that bind to the prostaglandin receptor increasing the outflow of the fluid from the eyes and reducing intraocular pressure. Beta-blockers are also commonly utilized topical drugs that act by reducing the production of fluid inside the eyes. Combination medications are eye drops used in patients who require more than one medication.
Cholinergic agents contract the ciliary muscles, tighten the trabecular meshwork, and increase the outflow of fluid. Carbonic anhydrase inhibitors and alpha agonists are employed to boost the outflow of fluid from the eyes, thereby reducing intraocular pressure. Prostaglandins, beta-blockers, and combination medication are the most widely used topical agents.
Glaucoma represents the leading cause of irreversible blindness worldwide. People with diabetes are likely to suffer from glaucoma. Diabetic retinopathy, which is a complication of diabetes and the most common form of diabetic eye disease, can increase the risk of glaucoma. Diabetes affects more than 29 million people in the U.S. Retinopathy damages the tiny blood vessels in the retina. It affects nearly 7.7 million people in the U.S. aged 40 years and older. According to the Centers for Disease Control’s National Diabetes Statistics Report for 2022, the number of diabetes cases reached 37.3 million in the U.S.
New glaucoma medications are effective in lowering intraocular pressure as they increase the outflow of aqueous humor. Netarsudil is a newer class of medication that works by increasing the outflow of aqueous humor and reducing intraocular pressure. In March 2023, Alembic Pharmaceuticals received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Brimonidine Tartrate Ophthalmic Solution, 0.15%. The drug is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
According to the latest glaucoma therapeutics market analysis, the hospitals end-user segment held largest share in 2022. A large population prefers visiting hospitals first rather than specialty clinics for treatment as the cost of therapy at hospitals is lower. Hospitals offer advanced diagnostic tools and techniques for monitoring intraocular pressure and other parameters relevant to glaucoma. This helps in the effective and targeted treatment of the disease.
According to the latest glaucoma therapeutics market insights, North America accounted for largest share in 2022, followed by Europe. Increase in geriatric population and rise in awareness regarding glaucoma are fueling the market dynamics of the region. According to The Glaucoma Research Foundation, three million people in the U.S. have glaucoma. Older adults are six times more likely to develop glaucoma after age 60. Availability of reimbursements and presence of well-established healthcare infrastructure are also boosting the demand for glaucoma therapeutics in North America.
The market in Asia Pacific is expected to advance at a high CAGR during the forecast period. Surge in prevalence of glaucoma is driving the glaucoma therapeutics market statistics in the region. According to the study ‘The Prevalence of Glaucoma and Its Related Factors in Rural Residents: A Cross-Sectional Study in Jiangxi, China’, the prevalence rate of glaucoma was 1.4% among the 5385 participants.
Major players are investing significantly in R&D activities to expand their product portfolio and increase their glaucoma therapeutics market share. AbbVie Inc., Merck & Co., Inc., Pfizer Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Bausch Health Companies Inc., and Alcon are major glaucoma therapeutics companies.
Each of these players has been profiled in the glaucoma therapeutics market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 8.3 Bn |
| Market Forecast Value in 2031 | US$ 13.5 Bn |
| Growth Rate (CAGR) | 5.5% |
| Forecast Period | 2023 to 2031 |
| Historical Data Available for | 2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 8.3 Bn in 2022
It is projected to grow at a CAGR of 5.5% from 2023 to 2031
Increase in prevalence and incidence of diabetic disorders and rise in geriatric population
The hospitals end-user segment held the largest share in 2022
North America held largest share in 2022
AbbVie Inc., Merck & Co., Inc., Pfizer Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Bausch Health Companies Inc., and Alcon
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glaucoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Therapeutics Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Glaucoma Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2023–2031
6.3.1. Prostaglandins
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Combination Medications
6.3.5. Cholinergics
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Glaucoma Therapeutics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Hospitals
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness Analysis, by End-user
8. Global Glaucoma Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2023–2031
9.3.1. Prostaglandins
9.3.2. Beta Blockers
9.3.3. Alpha Agonists
9.3.4. Combination Medications
9.3.5. Cholinergics
9.4. Market Value Forecast, by End-user, 2023–2031
9.4.1. Hospitals
9.4.2. Ophthalmic Clinics
9.4.3. Ambulatory Surgical Centers
9.5. Market Value Forecast, by Country, 2023–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By End-user
9.6.3. By Country
10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2023–2031
10.3.1. Prostaglandins
10.3.2. Beta Blockers
10.3.3. Alpha Agonists
10.3.4. Combination Medications
10.3.5. Cholinergics
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Ophthalmic Clinics
10.4.3. Ambulatory Surgical Centers
10.5. Market Value Forecast, by Country/Sub-region, 2023–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2023–2031
11.3.1. Prostaglandins
11.3.2. Beta Blockers
11.3.3. Alpha Agonists
11.3.4. Combination Medications
11.3.5. Cholinergics
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Ophthalmic Clinics
11.4.3. Ambulatory Surgical Centers
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2023–2031
12.3.1. Prostaglandins
12.3.2. Beta Blockers
12.3.3. Alpha Agonists
12.3.4. Combination Medications
12.3.5. Cholinergics
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Ophthalmic Clinics
12.4.3. Ambulatory Surgical Centers
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2023–2031
13.3.1. Prostaglandins
13.3.2. Beta Blockers
13.3.3. Alpha Agonists
13.3.4. Combination Medications
13.3.5. Cholinergics
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Ophthalmic Clinics
13.4.3. Ambulatory Surgical Centers
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. AbbVie Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Merck & Co., Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Pfizer Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Novartis AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Santen Pharmaceutical Co., Ltd.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Bausch Health Companies Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Alcon
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
List of Tables
Table 01: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 02: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 03: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 04: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 05: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 06: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 07: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 08: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 9: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 10: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 11: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 12: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 13: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 15: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
Table 16: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 17: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 18: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2023–2031
List of Figures
Figure 01: Global Glaucoma Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Glaucoma Therapeutics Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Glaucoma Therapeutics Market Value Share, by Drug Class, 2022
Figure 04: Global Glaucoma Therapeutics Market Revenue (US$ Mn), by End-user, 2022
Figure 05: Global Glaucoma Therapeutics Market Value Share, by End-user, 2022
Figure 06: Global Glaucoma Therapeutics Market Value Share, by Region, 2022
Figure 07: Global Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2023–2031
Figure 8: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
Figure 9: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 10: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 11: Global Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 12: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2023 and 2031
Figure 13: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
Figure 14: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 15: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 16: North America Glaucoma Therapeutics Market Value Share Analysis, by Country, 2023 and 2031
Figure 17: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
Figure 18: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 19: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 20: North America Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 21: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 22: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 23: Europe Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 24: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
Figure 25: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 26: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 27: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 28: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 29: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 30: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 31: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
Figure 32: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 33: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 35: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 36: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 38: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
Figure 39: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 40: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 41: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 42: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 43: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 44: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 45: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
Figure 46: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2031
Figure 47: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 48: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Glaucoma Therapeutics Market
